Goloudina et al. provided a comprehensive summary of shared neoantigens observed in cancer [16], highlighting frequent TP53 and KRAS mutations found in colorectal, lung, and pancreatic cancers, BRAF mutations in bladder, kidney, and thyroid cancers, EGFR mutations in hematological malignancies and lung cancer, IDH1 mutations in gliomas, and PIK3CA mutations in breast cancer. The gene discussed is KRAS; the disease is pancreatic neoplasm.